Role of proliferation in HER2 status predicted response to doxorubicin
Manuela Campiglio(Fondazione IRCCS Istituto Nazionale dei Tumori), Sylvie Ménard(Fondazione IRCCS Istituto Nazionale dei Tumori), Pinuccia Valagussa(Fondazione Michelangelo), Giovanni Luca Beretta(Fondazione IRCCS Istituto Nazionale dei Tumori), Andrea Balsari(University of Milan), Clelia Olgiati(University of Milan), Nadia Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Giulia Somenzi(University of Milan)
Cited by 57
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Isolation and <i>In vitro</i> Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties
|Cancer Research|2005|1.7k
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
|Journal of Clinical Oncology|2006|725